Attention Deficit and Disruptive Behavior Disorders Clinical Trials

Completed

Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.

NCT00216918

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +2 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Québec, Quebec, Canada

View Trial Details

Completed

Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

NCT00191633

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders, Attention-Deficit/Hyperactivity Disorder, +2 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Calgary, Alberta, Canada

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Edmonton, Alberta, Canada

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Abbotsford British Columbia, British Columbia, Canada

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Burnaby, British Columbia, Canada

View all 19 locations

View Trial Details

Completed

Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

NCT00191035

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders, Attention-Deficit/Hyperactivity Disorder, +2 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Pasadena, California, United States

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Rolling Hills Estates, California, United States

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Spring Valley, California, United States

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Norwich, Connecticut, United States

View all 21 locations

View Trial Details

Completed

Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD

NCT00382616

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders, Attention-Deficit/Hyperactivity Disorder, +13 more
Locations: Clinical Nutrition Unit, Sourasky Medical Center Tel Aviv, Israel

View Trial Details

Completed

Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents

NCT00191542

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +2 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Gothenburg, Sweden

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Huddinge, Sweden

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Linköping, Sweden

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Lund, Sweden

View Trial Details

Completed

Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder

NCT00191880

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +2 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Calgary, Canada

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Edmonton, Canada

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician London, Canada

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Montreal, Canada

View Trial Details

Completed

A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder

NCT00190931

Conditions: Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders, +2 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Columbia, Missouri, United States

View Trial Details

Completed

Risperidone Augmentation for Treatment-Resistant Aggression in ADHD

NCT00297739

Conditions: Aberrant Motor Behavior in Dementia, Aggression, Attention Deficit Disorder with Hyperactivity, +6 more
Locations: Jorge L. Armenteros, M.D., P.A. Coral Gables, Florida, United States

View Trial Details

Completed

Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder

NCT00223561

Conditions: ADHD, Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders, +2 more
Locations: Utrecht Institute for Pharmaceutical Sciences Utrecht, Netherlands

View Trial Details

Completed

Genetic Liability in the Brain Morphology of Attention Deficit Hyperactivity Disorder

NCT00161161

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders, +2 more
Locations: UMC Utrecht Utrecht, Netherlands

View Trial Details

Attention Deficit and Disruptive Behavior Disorders

Attention Deficit and Disruptive Behavior Disorders trial results

Related conditions